Helping patients reclaim a life of possibility
September is shaping up to be an extraordinary month for myeloma awareness and advocacy across MPE’s member network. From Portugal to Serbia, from Lithuania to Slovenia, our members are planning bold, impactful campaigns to raise awareness during Blood Cancer Awareness Month and European Myeloma Day on 27 September. Key member activities include: Portugal (APCL) is…
Myeloma Patients Europe (MPE) is attending and presenting at the International Myeloma Society (IMS) Annual Meeting taking place in Glasgow from 23–26 September 2026. The meeting, attended by over 3,000 delegates from around the world, features presentations on the most important data and topics in myeloma. MPE recently interviewed IMS President and member of the…
As part of our September European Young Myeloma Patients Group (EYMPG) meeting on Induced Menopause and Sexual Health in young myeloma patients, Filipa Lopes has shared her personal experience of treatment induced menopause. She was diagnosed with myeloma at the age of 29 and hopes her story encourages other young patients to seek support and…
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy. The CHMP is the European Medicines Agency’s (EMA) committee responsible for…
Myeloma Patients Europe has joined 14 other patient organisations members of the European Union Health Technology Assessment (EUHTA) stakeholder network to issue a joint statement on the publication of the first Joint Clinical Assessment (JCA) under the EU Health Technology Assessment Regulation (EUHTAR). The statement was coordinated by the European Patients Forum (EPF) and welcomes…
Myeloma Patients Europe (MPE) is proud to announce the launch of the Care Connect Programme, a new initiative dedicated to strengthening support for carers of people living with myeloma and AL amyloidosis across Europe. Carers play a vital role in the lives of patients, providing emotional support, practical assistance, care coordination, and advocacy throughout the myeloma pathway. However, feedback from MPE member organisations has…
MPE at EHA 2026: Stockholm in review EHA 2026 brought thousands of researchers, clinicians and patient advocates together in Stockholm for four days of cutting-edge science, discussion and connection. For the MPE team, it was a week of in-depth learning and valuable exchanges with stakeholders. What we did Across the congress we attended myeloma scientific…